On 15 March 2024, the Australian Department of Health and Aged Care published the public summary documents considered at the November 2023 PBAC meeting. Decisions included:
- Novo Nordisk’s Wegovy® (semaglutide) – PBAC refused PBS-listing for severe obesity;
- Organon’s Hadlima® (adalimumab) 40 mg in 0.4 mL PFP and PFS – PBAC recommended Authority Required listing for the same indications as Humira®;
- Generic Health’s Teriparatide Lupin® (teriparatide), biosimilar to Eli Lilly’s Forteo® – recommended for listing; and
- Gedeon Richter’s Terrosa® (teriparatide), biosimilar to Eli Lilly’s Forteo® – recommended for listing.